BACKGROUND Statins improve prognosis in patients with coronary heart diseases by decreasing the incidence of vascular events. Excess prevalence of hyperhomocysteinemia, an independent risk factor of cardiovascular diseases, has been observed in stable renal transplant recipients (RTRs). OBJECTIVES The objective of our study was to evaluate the association between atorvastatin administration a...

Statins reduce infarct size (IS) in ischemia-reperfusion injury of the myocardium. Inhibition of cyclooxygenase-2 (COX-2) attenuates this benefit. We investigated the effect of two widely used non-selective non-steroidal anti-inflammatory drugs (NSAIDs) with different degree of anti-COX-2 activity on atorvastatin-mediated preconditioning. Wistar rats received oral atorvastatin (10 mg∙kg-1∙day-1...

OBJECTIVE Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are known to enhance vascular expression of endothelial (eNOS) and inducible nitric oxide synthase (iNOS). In this study, we examined whether statins also upregulate vascular expression of neuronal NOS (nNOS). METHODS AND RESULTS In cultured rat aortic smooth muscle cells, treatment with atorvastatin ...

23 24 Purpose: Telaprevir is a hepatitis C virus protease inhibitor that is both a substrate and 25 an inhibitor of CYP3A. Amlodipine and atorvastatin are both substrates of CYP3A and 26 are amongst the drugs most frequently used by patients with hepatitis C. This study was 27 conducted to examine the effect of telaprevir on atorvastatin and amlodipine 28 pharmacokinetics (PK). 29 Methods: This...

Prevention and treatment of neuropathic pain (NP) is one of the most difficult problemsin clinical practice since the underlying mechanism of NP is unclear. In previous studies, theincreased production of nitric oxide (NO) has been closely linked to the induced NP. In thisstudy, we assessed the effect of atorvastatin through NO mechanism, on inflammation, thermalhyperalg...

AIMS The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients with the metabolic syndrome. METHODS AND RESULTS Patients with the metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) > or =3.36 mmol/L (130 mg/dL) and multiple risk factors conferring a 10-year coronary heart disease risk score of >10% were randomized (2:2:1) to receive rosuvast...

Background: This study was to investigate the clinical effect of high-dose atorvastatin on patients with acute cerebral infarction. Materials and Methods: 234 patients with acute cerebral infarction were randomized divided into control group (n=78), highdose atorvastatin (HDA) group (n=78) and low-dose atorvastatin (LDA) group (n=78). 80L group and 20L group were received lovastatin 80 mg/d or ...

introduction: drug interactions are considered as adverse effects of drugs that alter a patient’s response to an initial medication due to concurrent administration of different drugs or other substances. this study aimed to assess the role of medical education in reducing potential atorvastatin drug interactions in a teaching hospital by distributing alert cards and putting up posters in a nur...

Both hyperlipidemia and metabolic syndrome have adverse effect on tendon structure. Atorvastatin is most widely used antihyperlipidemic drug. Statins have adverse effects on the tendon. Many studies have analyzed the relationship between atorvastatin and skeletal muscles. Atorvastatin administered after the surgical repair of a ruptured tendon appears to affect revascularization, collagenizatio...

BACKGROUND Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiovascular death in the recent Investigation of Lipid Level Management to Understand its ...